P2RY2 and pancreatic ductal adenocarcinoma: A recent study demonstrated that activated Purinergic Receptor P2Y2 (P2RY2) contributed to the activation of the PI3K-mTOR pathway thus enhancing cancer glycolysis in pancreatic ductal adenocarcinoma [32].